The present invention provides a novel ligand for the dopamine D3 receptor and a preparation method therefor. The compound, and a pharmaceutically acceptable salt and a pharmaceutical combination or a pharmaceutical preparation thereof are used for the treatment and prevention of schizophrenia, neurodegenerative diseases, particularly Parkinson's disease, drug dependence, drug addiction, anxiety, depression, and the like. The novel ligand for the dopamine D3 receptor features a high affinity, a high specificity, and a high functional selectivity. The compound and the pharmaceutically acceptable salt and the pharmaceutical combination or the pharmaceutical preparation thereof can be used to study the distribution and function of dopamine D2 subtype receptors and diseases related to functional disorders thereof, and can also be used to improve hyperprolactinemia, extrapyramidal reactions, and levodopa-associated movement disorder or dyskinesia.
